Document ID: chunk:federal_register_of_legislation:F2024L00761:reg:9:p1
Version: federal_register_of_legislation:F2024L00761
Segment Type: reg
Provision Reference: reg 9 (pt 1/3)
Character Range: 4300–7915

9               Factors that must exist
At least one of the following factors must exist before it can be said that, on the balance of probabilities, cardiomyopathy or death from cardiomyopathy is connected with the circumstances of a person's relevant service:
(1)          undergoing a course of radiotherapy for cancer, where the heart was in the field of radiation, before clinical onset or clinical worsening;
(2)           having myocarditis before clinical onset or at the time of clinical worsening;
(3)          having infection with Trypanosoma cruzi (Chagas disease) before clinical onset or clinical worsening;
(4)          having infection with human immunodeficiency virus before clinical onset or clinical worsening;
(5)          having phaeochromocytoma or paraganglioma at the time of clinical onset or clinical worsening;
Note: paraganglioma and phaeochromocytoma are defined in the Schedule 1 – Dictionary.
(6)          having infiltration of the myocardium due to:
(a)          amyloidosis;
(b)          iron overload (haemosiderosis); or
(c)          sarcoidosis;
at the time of clinical onset or clinical worsening;
Note: iron overload is defined in the Schedule 1 - Dictionary.
(7)          having a primary or metastatic neoplasm infiltrating the myocardium at the time of clinical onset or clinical worsening;
(8)          having one of the following endocrine disorders:
(a)          acromegaly;
(b)          adrenal insufficiency;
(c)          Cushing syndrome;
(d)          diabetes mellitus;
(e)          hyperthyroidism, including goitre or Graves disease that has resulted in hyperthyroidism;
(f)           hypoparathyroidism;
(g)          hypothyroidism, including Hashimoto thyroiditis that has resulted in hypothyroidism;
(h)          primary hyperaldosteronism; or
(i)            thyrotoxicosis;
at the time of clinical onset or clinical worsening;
Note: acromegaly and primary hyperaldosteronism are defined in the Schedule 1 – Dictionary.
(9)          being obese at the time of clinical onset or clinical worsening;
Note: being obese is defined in the Schedule 1 - Dictionary.
(10)      having a clinically apparent nutritional deficiency involving:
(a)          carnitine;
(b)          selenium (Keshan disease); or
(c)          thiamine (wet beriberi);
at the time of clinical onset or clinical worsening;
(11)      having chronic renal failure at the time of clinical onset or clinical worsening as indicated by any of the following:
(a)          a glomerular filtration rate of less than 15 mL/min/1.73 m2 for a period of at least 3 months; or
(b)           undergoing chronic dialysis for renal failure;
(12)      having cirrhosis of the liver before clinical onset or clinical worsening;
(13)      taking one of the following medications within the 3 months before clinical onset or clinical worsening:
(a)          5-fluorouracil (non-topical);
(b)          alemtuzumab;
(c)          amphotericin B;
(d)          anagrelide;
(e)          bevacizumab;
(f)           cisplatin;
(g)          clozapine;
(h)          cobimetinib;
(i)            cyclophosphamide;
(j)            dasatinib;
(k)          exogenous catecholamine;
(l)            ifosfamide;
(m)        imatinib;
(n)          interferon alpha;
(o)          isotretinoin or tretinoin;
(p)          lithium;
(q)          methylphenidate;
(r)           mitomycin C;
(s)           olanzapine;
(t)            osimertinib;
(u)          paclitaxel (when used in combination with doxorubicin);
(v)          sunitinib;
(w)        tacrolimus;
(x)          trabectedin;
(y)          trametinib;
(z)          trastuzumab; or